Compugen Ltd. – NASDAQ:CGEN
Compugen Ltd. stock price today
$1.48
-0.09
-5.73%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 14 hours
Compugen Ltd. stock price monthly change
-10.79%
month
Compugen Ltd. stock price quarterly change
-10.79%
quarter
Compugen Ltd. stock price yearly change
-11.30%
year
Compugen Ltd. key metrics
Market Cap | 136.04M |
Enterprise value | N/A |
P/E | -1.59 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 7.16 |
Price/Book | 0.69 |
PEG ratio | -0.32 |
EPS | -0.19 |
Revenue | N/A |
EBITDA | -11.35M |
Income | -16.68M |
Revenue Q/Q | N/A |
Revenue Y/Y | 380.24% |
Profit margin | -449.25% |
Oper. margin | -471.65% |
Gross margin | 87% |
EBIT margin | -471.65% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCompugen Ltd. stock price history
Compugen Ltd. stock forecast
Compugen Ltd. financial statements
| Jun 2023 | 0 | -9.27M | |
|---|---|---|---|
| Sep 2023 | 0 | -9.85M | |
| Dec 2023 | 33.45M | 9.71M | 29.03% |
| Mar 2024 | 2.55M | -7.26M | -283.98% |
| Dec 2023 | 33.45M | 9.71M | 29.03% |
|---|---|---|---|
| Mar 2024 | 2.55M | -7.26M | -283.98% |
| Sep 2025 | 4.99M | -3.58M | -71.63% |
| Dec 2025 | 5.58M | -2.68M | -48.05% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 77055000 | 15.05M | 19.54% |
|---|---|---|---|
| Sep 2023 | 67611000 | 14.38M | 21.27% |
| Dec 2023 | 121334000 | 55.77M | 45.97% |
| Mar 2024 | 113702000 | 54.02M | 47.52% |
| Dec 2022 | -23.03M | 40.38M | -18.41M |
|---|---|---|---|
| Mar 2023 | 0 | 0 | 0 |
| Jun 2023 | 0 | 0 | 0 |
| Sep 2023 | 0 | 0 | 0 |
Compugen Ltd. alternative data
| Sep 2023 | 69 |
|---|---|
| Oct 2023 | 69 |
| Nov 2023 | 69 |
| Dec 2023 | 69 |
| Jan 2024 | 69 |
| Feb 2024 | 69 |
| Mar 2024 | 68 |
| Apr 2024 | 68 |
| May 2024 | 68 |
| Jun 2024 | 68 |
| Jul 2024 | 68 |
Compugen Ltd. other data
24.46%
-21.02%
of CGEN is owned by hedge funds
67
-16
21.15M
-17.14M
shares is hold by hedge funds
| Patent |
|---|
Application Filling date: 28 Jul 2020 Issue date: 8 Sep 2022 |
Application Filling date: 6 Apr 2020 Issue date: 2 Jun 2022 |
Application POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER Filling date: 18 May 2021 Issue date: 17 Feb 2022 |
Grant Filling date: 1 Jun 2018 Issue date: 18 Jan 2022 |
Grant Filling date: 27 Sep 2016 Issue date: 11 Jan 2022 |
Application Filling date: 18 Nov 2020 Issue date: 19 Aug 2021 |
Application Filling date: 17 Jun 2020 Issue date: 24 Jun 2021 |
Application Filling date: 17 Jun 2020 Issue date: 7 Jan 2021 |
Application Filling date: 28 Jan 2020 Issue date: 10 Dec 2020 |
Application Filling date: 28 Nov 2018 Issue date: 26 Nov 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 20 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 5 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 7 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Anat Cohen-Dayag (1967) Chief Executive Officer, Pres & Director | $989,870 |
Dr. Henry Adewoye M.D. (1965) Senior Vice President & Chief Medical Officer | $589,090 |
Mr. Ari Krashin (1973) Chief Financial & Operating Officer | $545,180 |
Dr. Oliver Froescheis Ph.D. (1966) Senior Vice President of Corporation & Bus. Devel. | $453,250 |
Dr. Zurit Levine (1968) Senior Vice President of Technology Innovation | $339,190 |
-
What's the price of Compugen Ltd. stock today?
One share of Compugen Ltd. stock can currently be purchased for approximately $1.48.
-
When is Compugen Ltd.'s next earnings date?
Unfortunately, Compugen Ltd.'s (CGEN) next earnings date is currently unknown.
-
Does Compugen Ltd. pay dividends?
No, Compugen Ltd. does not pay dividends.
-
How much money does Compugen Ltd. make?
Compugen Ltd. has a market capitalization of 136.04M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 346.12% to 33.46M US dollars.
-
What is Compugen Ltd.'s stock symbol?
Compugen Ltd. is traded on the NASDAQ under the ticker symbol "CGEN".
-
What is Compugen Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Compugen Ltd.?
Shares of Compugen Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Compugen Ltd.'s key executives?
Compugen Ltd.'s management team includes the following people:
- Dr. Anat Cohen-Dayag Chief Executive Officer, Pres & Director(age: 58, pay: $989,870)
- Dr. Henry Adewoye M.D. Senior Vice President & Chief Medical Officer(age: 60, pay: $589,090)
- Mr. Ari Krashin Chief Financial & Operating Officer(age: 52, pay: $545,180)
- Dr. Oliver Froescheis Ph.D. Senior Vice President of Corporation & Bus. Devel.(age: 59, pay: $453,250)
- Dr. Zurit Levine Senior Vice President of Technology Innovation(age: 57, pay: $339,190)
-
How many employees does Compugen Ltd. have?
As Jul 2024, Compugen Ltd. employs 68 workers.
-
When Compugen Ltd. went public?
Compugen Ltd. is publicly traded company for more then 25 years since IPO on 11 Aug 2000.
-
What is Compugen Ltd.'s official website?
The official website for Compugen Ltd. is cgen.com.
-
How can i contact Compugen Ltd.?
Compugen Ltd. can be reached via phone at +972 3 765 8585.
Compugen Ltd. company profile:
Compugen Ltd.
cgen.comExchange:
NASDAQ
Full time employees:
68
Industry:
Biotechnology
Sector:
Healthcare
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Azrieli Center
Holon, 5885849
Holon, 5885849
CIK: 0001119774
ISIN: IL0010852080
CUSIP: M25722105
